Form 4 for HAE HAEMONETICS CORP
Accepted 2025-06-09 00:00:00 ET · period of report 2025-06-05 · accession 0001127602-25-017102 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-09 | 2025-06-05 | HAE | Maunsell Farris Maryanne | VP, CAO | A - Grant | — | +2,662 | 4,478 | +147% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-05 | A | A | 2,662 | — | 4,478 | D | — | — | (F1) The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. Two-thirds of the RSUs vest in two equal annual installments beginning on the first anniversary of the date of grant and one-third of the RSUs vests based on the Issuer's common stock price at the end of a two-year performance period. (F2) Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. (F3) This number includes unvested RSUs previously reported. |